Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020

On May 18, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held June 22-24, 2020 (Press release, Seattle Genetics, MAY 18, 2020, View Source [SID1234558243]). Registration information to attend the virtual sessions can be found here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will have a strong presence at the AACR (Free AACR Whitepaper) annual meeting with 12 data presentations highlighting our leadership in antibody-drug conjugate innovation and the depth and potential of our growing oncology pipeline of targeted therapies," said Scott Peterson, Ph.D., Senior Vice President of Research at Seattle Genetics. "Of key importance, a number of presentations will feature advances in our drug linker and payload components of ADCs. Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas."

Dr. Peterson added, "In addition to our ADC technologies, we will also be presenting preclinical data highlighting the activity of our HER2 selective tyrosine kinase inhibitor tucatinib in preclinical models of HER2 mutant driven cancers and in the CNS setting. We look forward to sharing these presentations with the community at the second AACR (Free AACR Whitepaper) virtual meeting."

Abstracts can be found at www.aacr.org and include the following poster presentations below.

New ADC Technology Advances

Abstract Title: Novel Framework for Quantifying Synergy in High-Throughput Drug Combination Cytotoxicity Experiments (Abstract #835)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics

Abstract Title: Discovery of a Tripeptide-Based Camptothecin Drug-Linker for Antibody-Drug Conjugates with Potent Antitumor Activity and a Broad Therapeutic Window (Abstract #2885)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Characterization of Payload Release from a Novel Camptothecin Drug-Linker (Abstract #2895)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Pipeline Programs

Abstract Title: SGN-CD30C, a New CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti-Tumor Activity and Superior Tolerability in Preclinical Studies (Abstract #2889)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Utilizing PDX Models to Better Understand Factors that Predict Response to SGN-CD228A, an Antibody-Drug Conjugate (ADC) for Solid Tumors (Abstract #2888)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SGN-B6A: A New MMAE ADC Targeting Integrin Beta-6 in Multiple Carcinoma Indications (Abstract #2906)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SEA-CD40 is a Non-Fucosylated Anti-CD40 Antibody with Potent Pharmacodynamic Activity in Preclinical Models and Patients with Advanced Solid Tumors (Abstract #5535)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immune Response to Therapies 1

Commercial-Stage Programs

Abstract Title: Preclinical Characterization of Tucatinib in HER2-Amplified Xenograft and CNS Implanted Tumors (Abstract #1962)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Small Molecule Therapeutic Agents

Abstract Title: Tucatinib Inhibits Creatinine and Metformin Renal Tubule Secretion but has No Effect on Renal Function (GFR) (Abstract #3015)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib Inhibits CYP3A, CYP2C8 and P-gp-Mediated Elimination and is Impacted by CYP2C8 Inhibition in Healthy Volunteers (Abstract #3016)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib, a Selective Small Molecule HER2 Inhibitor, is Active in HER2 Mutant Driven Tumors (Abstract #4222)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Tyrosine Kinase and Phosphatase Inhibitors

Abstract Title: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urotherlial Cancers (Abstract #5581)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immunotherapy

LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer

On May 18, 2020 LIPAC Oncology LLC reported the presentation of positive interim data from the TD-001 trial evaluating the safety and efficacy of investigational agent LiPax (paclitaxel) for intravesical instillation in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC) (Press release, Lipac Oncology, MAY 18, 2020, View Source [SID1234558259]). The study was accepted for presentation at the 2020 American Urological Association (AUA) Annual Meeting, published as a supplement to the April 2020 issue of The Journal of Urology and presented as part of the AUA Virtual Experience. The presentation can be accessed via the AUA website here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Trial results showed 100% (6/6) of patients treated with Transurethral Resection of Bladder Tumor (TURBT) and LiPax achieved a complete response three, six and nine months after the start of therapy. The 12-month recurrence free survival rate was 85% (5/6) and 100% (3/3) for all patients that reached the 18-month mark. Follow-up will continue until all patients have reached the 24-month mark.

"By pairing a simple outpatient procedure (TURBT) with LiPax, we have an opportunity to substantially improve both clinical outcomes and quality of life for people living with highly recurrent NMIBC," said Michael Oefelein, M.D., Chief Medical Officer of LIPAC Oncology. "This positive data validates that our proliposomal technology platform increases penetration and persistence of treatment and significantly improves the effectiveness of intravesical therapy."

Based on the biopsy results obtained from TURBT, NMIBC is stratified into three risk categories: low, intermediate, and high risk. To reduce recurrence and prevent progression, The AUA NMIBC guidelines recommend various durations of intravesical therapy after TURBT. The low to intermediate risk category is estimated to comprise 90,000 Americans, yet no intravesical agent is approved by the U.S. Food and Drug Administration for this disease.

In the study, LiPax was well tolerated with no change in patient reported urinary health related quality of life, no dose limiting toxicity (grade 3 or greater severity adverse events), and no evidence of systemic exposure to the active product ingredient (paclitaxel).

About The Phase 1/2a TD-001 Trial
TD-001 is an open-label, single-arm, multi-center Phase 1/2a clinical trial of TSD-001 (paclitaxel) for intravesical instillation to evaluate its safety and efficacy in patients with low to intermediate risk NMIBC.

About LiPax
LiPax (paclitaxel) for intravesical instillation is an investigational drug formulation of paclitaxel in Phase 2 development for the treatment of NMIBC. Utilizing the proliposomal technology platform, LIPAC Oncology’s proprietary formulation to enhance persistence and penetration of bladder tissue to paclitaxel, is designed to enhance the standard of care of outpatient endoscopic tumor removal, histological risk assessment followed by intravesical instillation using a standard urinary catheter. LIPAC Oncology completed enrollment in TD-001 in May 2020 and intends to advance the program to a pivotal study to further investigate LiPax in the treatment of this condition.

MIRATI THERAPEUTICS APPOINTS JOSEPH A. LEVEQUE, M.D. AS CHIEF MEDICAL OFFICER

On May 18, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020 (Press release, Mirati, MAY 18, 2020, View Source [SID1234558276]). Isan Chen, M.D., will step down as Chief Medical and Development Officer to lead an early-stage biotech company, however, Dr. Chen will continue to act as an advisor to Mirati.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Isan’s leadership over the last seven years has been central to the advancement of our programs," said Dr. Charles Baum, M.D., Ph.D., President and Chief Executive Officer at Mirati Therapeutics. "We appreciate his dedicated service which brought Mirati from a small oncology company to where we are today. We wish him well and know he will be successful in this new opportunity."

"Joe’s experience with world class clinical development teams that have brought several novel oncology therapies to patients will have an important impact as we prepare for Mirati’s next phase of growth," said Dr. Baum. "We are thrilled to have him join Mirati as we rapidly advance our registration-enabling clinical trials for both sitravatinib and MRTX849, as well as advance our preclinical pipeline including the KRAS G12D inhibitor program."

Dr. Leveque joins Mirati following his successful tenure as Chief Medical Officer at Synthorx, which was acquired by Sanofi in late 2019. Prior to Synthorx, he served as Chief Medical Officer at ARMO Biosciences, a late-stage immuno-oncology company that was acquired by Eli Lilly in May 2018. Prior to these roles, Dr. Leveque was Chief Medical Officer of EMD Serono, the North American subsidiary of Merck KGaA, and Vice President and Head of U.S. Medical Oncology at Bristol-Myers Squibb, where he led the development and commercialization of the first generation of immuno-oncology therapeutics. He has also held key medical leadership positions at Onyx Pharmaceuticals, Cephalon Oncology and Amgen.

Dr. Leveque earned a Medical Doctorate from The University of Texas School of Medicine in Houston, TX and completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center, a teaching affiliate of the University of California, Los Angeles (UCLA). In addition, Dr. Leveque holds a Master of Business Administration from the Wharton School of the University of Pennsylvania.

In connection with his employment, the Compensation Committee of Mirati’s Board of Directors granted Dr. Leveque an inducement award consisting of a non-qualified stock option to purchase shares of common stock with a grant date fair value equal to $3,500,000 and restricted stock units with a grant date fair value equal to $2,500,000 ("RSUs"). The stock option has an exercise price per share equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on May 18, 2020 and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months subject to Dr. Leveque’s continued service relationship with Mirati through the applicable vesting dates. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the vesting commencement date, subject to Dr. Leveque’s continued service relationship with Mirati through the applicable vesting dates. The Compensation Committee of Mirati’s Board of Directors approved the awards as inducement material to Dr. Leveque’s employment in accordance with NASDAQ Listing Rule 5635(c)(4).

Blue Earth Diagnostics Announces Results from Early Clinical Experience with Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Men with Intermediate and High-risk Prostate Cancer

On May 18, 2020 Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, reported results from early clinical experience in Germany with positron emission tomography/computed tomography (PET/CT) imaging using rhPSMA-7.3 (18F), a radiohybrid Prostate Specific Membrane Antigen-targeted compound (Press release, Blue Earth Diagnostics, MAY 18, 2020, View Source [SID1234558228]). The results were presented by the Technical University of Munich (TUM) in an oral presentation at the American Urological Association’s AUA2020 Virtual Meeting on May 15, 2020. Results of the retrospective analysis of 56 patients with intermediate or high-risk prostate cancer indicated that rhPSMA-7.3 (18F) PET/CT demonstrated a patient-level sensitivity of 81%, specificity of 88% and diagnostic accuracy of 86%, when on-site image interpretations were compared to histopathological findings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Blue Earth Diagnostics is conducting two Phase 3 clinical trials of rhPSMA-7.3 (18F) PET imaging. The LIGHTHOUSE study (NCT04186819) will examine the potential use of rhPSMA-7.3 (18F) in newly diagnosed prostate cancer, and the SPOTLIGHT study (NCT04186845) is focused on its potential use in biochemical recurrent prostate cancer. Results from the early clinical experience by TUM, including with rhPSMA-7.3 (18F) PET, were included Blue Earth Diagnostics’ Investigational New Drug (IND) submission.

"We are very pleased that TUM is able to share the results of this early clinical experience with the prestigious urology community through the Virtual Science platform at AUA2020," said Jonathan Allis, D. Phil., CEO of Blue Earth Diagnostics. "Blue Earth Diagnostics has rapidly advanced our rhPSMA-7.3 (18F) research program since acquiring exclusive rights to theranostic rhPSMA technology in 2018, in line with our strategy to expand and advance a world-leading prostate cancer radiopharmaceutical portfolio. Both rhPSMA-7.3 (18F) and approved, commercially available Axumin (fluciclovine F 18) have unique and complementary mechanisms of action, and we believe that each may ultimately allow physicians and their patients flexibility in selecting the diagnostic agent most appropriate to each specific clinical situation."

"The ability to effectively stage primary prostate cancer is important in determining appropriate management for these patients," said Tobias Maurer, MD, of the Martini-Klinik and Department of Urology, University of Hamburg-Eppendorf, Germany (previously in the Department of Urology at TUM), who presented the results at AUA2020. "This retrospective analysis is the first report investigating the potential efficacy of the single isomer product rhPSMA-7.3 (18F), in PET imaging for primary lymph node staging in patients with intermediate and high-risk prostate cancer. Our study results indicated that rhPSMA-7.3 (18F) PET demonstrated 86% accuracy in men with primary prostate cancer. These preliminary data are encouraging and we are pleased that further research is ongoing."

"TUM’s early experience with radiohybrid PSMA agents has allowed us to investigate the potential diagnostic performance of this new class of theranostic PSMA-targeting agents, which can be efficiently labeled with imaging radioisotopes such as 18F for PET imaging or with 177Lu for therapeutic use," said Matthias Eiber, attending physician, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM. "PSMA-targeted imaging agents labeled with 18F offer potential advantages that are important considerations in detecting and localizing prostate cancer – broad availability, based on the radioisotope’s 110-minute half-life; consistent, centralized manufacturing with high batch production and high resolution PET scans."

Diagnostic efficacy of F-18-rhPSMA-7.3 PET Imaging for N-staging in Intermediate and High-Risk Prostate Cancer Patients Validated by Histopathology

The oral presentation detailed a 56-patient retrospective analysis investigating the efficacy of rhPSMA-7.3 (18F) PET/CT for primary lymph node staging in patients with intermediate and high-risk prostate cancer, spearheaded by Thomas Langbein, resident, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM. Results from on-site reads were compared to morphological imaging and validated by histopathology. Patient-based analysis indicated that the sensitivity, specificity and diagnostic accuracy of rhPSMA-7.3 (18F) PETimaging were 81.3% (95% CI, 54.4–96.0%), 87.5 (95% CI, 73.2–95.8%) and 85.7% (95% CI, 73.8–93.6%), respectively. Those for morphological imaging were 33.3% (95% CI, 13.3–59.0%), 89.5% (95% CI, 75.2–97.1%) and 71.4% (95% CI, 57.8–82.7%), respectively. On template-based analysis, the sensitivity, specificity and accuracy of rhPSMA-7.3 (18F) PET were 63.6% (95% CI, 45.4-79.6%), 97.9% (95% CI, 95.5-99.2%) and 94.4% (95% CI, 91.2-96.6%), respectively, and those for morphological imaging were 15.2% (95% CI, 5.11-31.9%), 99.3%(95% CI, 97.5-99.9%) and 90.6% (95% CI, 86.9-93.6%), respectively. The mean PSA level of the patients in this primary prostate cancer study was 11.0 ng/mL.

About rhPSMA

rhPSMA-7.3 (18F) consists of a radiohybrid Prostate-Specific Membrane Antigen (PSMA)-targeted receptor ligand which attaches to and is internalized by prostate cancer cells, and is labeled with the 18F radioisotope for PET imaging. rhPSMA compounds can also be labeled with radioisotopes such as 177Lu and 225Ac for therapeutic use. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA imaging technology from Scintomics in 2018, with an option to therapeutic rights. rhPSMA originated from the Technical University of Munich, Germany, and has been utilized clinically under German legislation at the Department of Nuclear Medicine there for the diagnostic imaging of men with both primary and recurrent prostate cancer. rhPSMA compounds have not received regulatory approval.

NOTE: Axumin (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

This press release is intended to provide information about Blue Earth Diagnostics’ business in the United States and Europe. Please be aware that the approval status and product label for Axumin varies by country worldwide. For EU Axumin product information refer to: View Source;mid=WC0b01ac058001d124.

U.S. Indication and Important Safety Information About Axumin

INDICATION

Axumin (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
Adverse reactions were reported in ≤ 1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.
To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

On May 18, 2020 Provectus (OTCQB: PVCT) reported the publication of an abstract about and data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2020 Virtual Annual Meeting II, to be held June 22-24, 2020 (Press release, Provectus Biopharmaceuticals, MAY 18, 2020, View Source [SID1234558244]). The abstract was posted online by AACR (Free AACR Whitepaper) on May 15 in advance of the virtual meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Small molecule-based PV-10 is administered either by cutaneous intratumoral (IT) injection to superficial melanoma and non-melanoma skin cancer tumors (such as basal cell carcinoma, Merkel cell carcinoma, and squamous cell carcinoma) or by percutaneous IT injection to visceral primary and metastatic tumors of the liver (such as hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and metastatic uveal melanoma). By targeting tumor cell lysosomes, PV-10 treatment may yield immunogenic cell death in solid tumor cancers that results in tumor-specific reactivity in circulating T cells.1-4

Abstract:

Title: Association of heat shock proteins as chaperone for STING: A potential link in a key immune activation mechanism revealed by the novel anti-cancer agent PV-10
Session Category: Clinical Research
Track(s): Clinical Research Excluding Trials, Immunology
Session Title: Inflammation, Immunity, and Cancer/Modifiers of the Tumor Microenvironment 1
Abstract number: 5393
This work was led by Aru Narendran, MD, PhD and his team of researchers at the Alberta Children’s Hospital Research Institute and the University of Calgary (Calgary, Alberta, Canada), who previously showed that PV-10 treatment mediates another immune system signaling pathway (poly-ADP ribose polymerase [PARP] cleavage)5.

About PV-10

PV-10 is an investigational new drug undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver (including metastatic neuroendocrine tumors and metastatic uveal melanoma). PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (like neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma) and pediatric blood cancers (like leukemia).5,6

Tumor Cell Lysosomes as the Seminal Drug Target

Lysosomes are the central organelles for intracellular degradation of biological materials, and nearly all types of eukaryotic cells have them. Discovered by Christian de Duve, MD in 1955, lysosomes are linked to several biological processes, including cell death and immune response. In 1959, de Duve described them as ‘suicide bags’ because their rupture causes cell death and tissue autolysis. He was awarded the Nobel Prize in 1974 for discovering and characterizing lysosomes, which are also linked to each of the three primary cell death pathways: apoptosis, autophagy, and necrosis.

Building on the Discovery, Exploration, and Characterization of Lysosomes

Cancer cells, particularly advanced cancer cells, are very dependent on effective lysosomal functioning.7 Cancer progression and metastasis are associated with lysosomal compartment changes8,9, which are closely correlated with (among other things) invasive growth, angiogenesis, and drug resistance10.

PV-10 selectively accumulates in the lysosomes of cancer cells upon contact, disrupting the lysosomes and causing the cells to die. Provectus1,11, external collaborators6, and other researchers13,14,16 have independently shown that PV-10 (RB) triggers each of the three primary cell death pathways: apoptosis, autophagy, and necrosis.

Cancer Cell Autolytic Death via PV-10: PV-10 induced autolytic cell death, or death by self-digestion, in Hepa1-6 murine HCC cells can be viewed in this Provectus video of the event (ethidium homodimer 1 [ED-1] stains DNA, but is excluded from intact nuclei; lysosensor green [LSG] stains intact lysosomes; the video is provided in 30-second frames; the event has a duration of approximately one hour). Exposure to PV-10 triggers the disruption of lysosomes, followed by nucleus failure and autolytic cell death. Identical responses have been shown by the Company in HTB-133 human breast carcinoma (which can be viewed in this Provectus video; this event has a duration of approximately two hours) and H69Ar human multidrug-resistant small cell lung carcinoma. Cancer cell autolytic cell death was reproduced by research collaborators from POETIC using relapsed and refractory human pediatric neuroblastoma cells to show that lysosomes are disrupted upon exposure to PV-10.5

Immune Signaling Pathways: PV-10 causes acute autolytic destruction of injected tumors (i.e., cell death), mediating several identified immune signaling pathways studied to date, such as the release of danger-associated molecular pattern molecules (DAMPs) and tumor antigens that initiate an immunologic cascade where local response by the innate immune system facilitates systemic anti-tumor immunity by the adaptive immune system. The DAMP release-mediated adaptive immune response activates lymphocytes, including CD8+ T cells, CD4+ T cells, and NKT cells, based on clinical and preclinical experience in multiple tumor types. Other mediated immune signaling pathways that have been identified include PARP cleavage5 and, now, stimulator of interferon genes (STING), which plays an important role in innate immunity15. PV-10 is the first cancer drug that may facilitate multiple, complementary, immune system signaling pathways.16

Orphan Drug Designations (ODDs)

ODD status has been granted to PV-10 by the U.S. Food and Drug Administration for the treatments of metastatic melanoma in 2006, hepatocellular carcinoma in 2011, neuroblastoma in 2018, and ocular melanoma (including uveal melanoma) in 2019.

Drug Product

Rose bengal disodium (RB) (4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein disodium salt) is a small molecule halogenated xanthene and PV-10’s active pharmaceutical ingredient. PV-10 drug product is a formulation of 10% w/v RB in 0.9% saline, supplied in single-use glass vials containing 5 mL (to deliver) of solution, and administered without dilution to solid tumors via IT injection.

Intellectual Property (IP)

Provectus’ IP includes a family of US and international (a number of countries in Asia, Europe, and North America) patents that protect the process by which pharmaceutical grade RB and related halogenated xanthenes are produced, reducing the formation of previously unknown impurities that exist in commercial grade RB in uncontrolled amounts. The requirement to control these impurities is in accordance with International Council on Harmonisation (ICH) guidelines for the manufacturing of an injectable pharmaceutical. US patent numbers are 8,530,675, 9,273,022, and 9,422,260, with expirations ranging from 2030 to 2031.

The Company’s IP also includes a family of US and international (a number of countries in Asia, Europe, and North America) patents that protect the combination of PV-10 and systemic immunomodulatory therapy (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 agents) for the treatment of a range of solid tumor cancers. US patent numbers are 9,107,887, 9,808,524, 9,839,688, and 10,471,144, with expirations ranging from 2032 to 2035.